We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Genetic Risk Factors Found in Gestational Diabetes

By LabMedica International staff writers
Posted on 26 Feb 2020
Print article
Image: Illumina microarrays are a robust system that allow investigators to find variants in simple nucleotide polymorphisms (SNPs). The microarrays are subsequently scanned in the iScan system (Photo courtesy of LABSERGEN LANGEBIO).
Image: Illumina microarrays are a robust system that allow investigators to find variants in simple nucleotide polymorphisms (SNPs). The microarrays are subsequently scanned in the iScan system (Photo courtesy of LABSERGEN LANGEBIO).
Gestational diabetes mellitus (GDM) is a common pregnancy complication affecting 6%–15% of pregnancies globally. Although the condition resolves after delivery in most cases, women with a history of GDM have a more than sevenfold increased risk of developing type 2 diabetes (T2D) compared with women with a normoglycemic pregnancy.

Individual single nucleotide polymorphisms (SNPs) and genetic risk scores (GRSs) capturing the cumulative risk conferred by these SNPs have been associated with T2D risk in the general population. However, as women with a history of GDM already have an elevated baseline genetic risk for T2D compared with the general population. The role genetic factors play in the development of T2D among women with a history of GDM may differ from that in the general population.

A team of scientists at the at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (Rockville, MD, USA) sought to gauge whether genetic risk scores could distinguish women with a history of gestational diabetes who develop T2D from those who do not. They applied this score to two population cohorts, one from the USA and one from Denmark, to find that women with high genetic risk scores were more likely to go on to develop T2D. Their findings also indicated that eating healthy could mitigate some of that risk.

Genotyping was performed using the TaqMan quantitative polymerase chain reaction (PCR) method (Applied Biosystems, Foster City, CA, USA) in 1,855 study participants from the USA and 603 from Denmark. In all, 112 candidate SNPs were selected based on previous genome- wide association studies (GWAS) of T2D. Genotyping was additionally performed using high- density SNP markers platforms, including, HumanHap, Infinium, OncoArray or Infinium HumanCoreExome (Illumina, San Diego, CA, USA).

Based on recent genome-wide association studies in European populations, the scientists identified 59 SNPs associated with T2D risk that they bundled into a genetic risk score for the condition. They then genotyped 2,434 white women with a history of gestational diabetes from the US Nurses' Health Study II and the Danish National Birth Cohort and determined their genetic risk scores. Of the women in the study, 601 developed T2D during the median follow-up period of 21 years for the US cohort and 13 years for the Danish cohort.

A high genetic risk score was associated with increased risk of developing T2D in both the US and Danish cohorts. When broken up by quartiles, the highest-scoring group was 19% more likely to develop T2D than the lowest scoring group. Every five risk alleles were associated with a 7% increase in T2D risk in the US cohort and 9% increase in risk in the Danish cohort.

The authors concluded that in a study based on two independent populations with a long follow- up period, they observed a significant association of genetic risk factors with the development of T2D. The magnitude of association, however, was modest. The study was published on February 13, 2020 in the journal BMJ Open Diabetes Research & Care.

Related Links:
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Applied Biosystems
Illumina


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.